SARS-CoV-2 IgG Antibody Levels After Inactivated Vaccine (CoronaVac) Among Elderly

Overview

Journal Infect Dis Clin Microbiol

Date 2024 Apr 18

PMID 38633340

Authors

Harika Oyku Dinc

Ilker Inanc Balkan

Beyhan Budak

Mehmet Demirci

Dogukan Ozbey

Ridvan Karaali

Bilgul Mete

Gunay Can

Sevgi Ergin

Bekir Kocazeybek

Nese Saltoglu

Affiliations

Soon will be listed here.

Abstract

We aimed to describe the antibody response against SARS-CoV-2 after inactivated COVID-19 vaccine in elderly individuals. SARS-CoV-2 IgG levels were measured in the blood samples of 126 volunteers over the age of 60. The antibody positivity rate was 42.8% after the first dose and 96.8% after the second dose of the vaccine. The median antibody titers after two vaccine doses were 561.3AU/mL and 43AU/mL, respectively(<0.001). After vaccination, 22.2% of the participants had antibodies equivalent to 1:80 dilutions in plaque reduction neutralization test (PNRT). We believe that the booster dose is needed to continue the protective immune response in especially elderly groups.

Citing Articles

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines - A prospective multi-center study.

Phuensan P, Sirimongkolkasem J, Tantawichien T, Phannajit J, Kerr S, Hansasuta P Heliyon. 2024; 10(1):e23246.

PMID: 38163241 PMC: 10756999. DOI: 10.1016/j.heliyon.2023.e23246.

References

Karamese M, Tutuncu E . The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older. J Med Virol. 2021; 94(1):173-177. PMC: 8662297. DOI: 10.1002/jmv.27289. View

Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z . Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021; 21(6):803-812. PMC: 7906628. DOI: 10.1016/S1473-3099(20)30987-7. View

Walker P, Whittaker C, Watson O, Baguelin M, Winskill P, Hamlet A . The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science. 2020; 369(6502):413-422. PMC: 7292504. DOI: 10.1126/science.abc0035. View

Bayram A, Demirbakan H, Gunel Karadeniz P, Erdogan M, Kocer I . Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol. 2021; 93(9):5560-5567. PMC: 8242724. DOI: 10.1002/jmv.27098. View

Flaxman S, Mishra S, Gandy A, Unwin H, Mellan T, Coupland H . Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020; 584(7820):257-261. DOI: 10.1038/s41586-020-2405-7. View